Aquestive Therapeutics, Inc.

AQST

Aquestive Therapeutics, Inc.

AQST

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-06-23Shares Purchased (TTM):0Shares Sold (TTM):730,717

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:64,843,906Shares Outstanding:122,609,995Institutional Ownership Pct.:52.89%

Earnings Market Reaction:

Filing Date:2026-08-11Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	98	111	121	129	61	69	72	78	90	95	24	25
Receivables Net Current	9	7	18	-	-	-	7	-	-	-	8	-
Inventory Net	7	8	6	8	8	7	6	7	7	8	7	7
Prepaid Expense And Other Assets Current	3	5	4	3	1	3	3	2	1	2	2	2
Assets Current	118	130	149	152	82	89	88	97	104	113	41	42
Property Plant And Equipment Net	4	4	4	4	4	4	4	4	4	4	4	5
Operating Lease Right Of Use Asset	8	4	5	5	5	5	5	5	5	5	6	6
Finite Lived Intangible Assets Net	-	-	0	-	-	0	0	0	0	1	1	1
Other Assets Noncurrent	2	3	3	3	3	4	4	4	4	5	5	5
Assets	132	141	160	164	94	102	101	110	118	130	57	59
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	9	12	30	11	12	12	10	8	6	11	9	10
Accrued Liabilities Current	5	3	5	5	5	3	6	5	6	5	6	5
Operating Lease Liability Current	1	1	1	1	1	1	1	0	0	0	0	0
Contract With Customer Liability Current	1	1	1	1	1	1	1	1	1	2	2	3
Lines Of Credit Current	-	-	10	-	-	-	0	-	-	-	0	-
Loans Payable Current	-	14	-	6	3	0	-	0	0	0	-	5
Liabilities Current	16	32	48	26	23	18	19	15	14	18	18	24
Long Term Loans Payable	-	-	-	-	-	-	-	-	-	-	-	35
Unsecured Long Term Debt	-	-	-	-	-	-	-	19	17	16	-	-
Long Term Debt And Capital Lease Obligations	51	25	28	-	-	-	33	-	-	-	28	-
Operating Lease Liability Noncurrent	8	4	4	5	5	5	5	5	5	5	5	6
Contract With Customer Liability Noncurrent	19	19	19	20	20	20	20	20	22	32	32	33
Other Liabilities Noncurrent	6	6	7	2	2	2	2	2	2	2	2	2
Liabilities	189	175	194	168	166	163	162	155	153	166	164	162
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	421	421	413	411	327	325	303	301	299	296	213	208
Retained Earnings Accumulated Deficit	-478	-455	-447	-415	-400	-386	-363	-346	-335	-332	-319	-311
Stockholders Equity	-57	-34	-34	-4	-73	-61	-60	-45	-35	-36	-106	-103
Liabilities And Stockholders Equity	132	141	160	164	94	102	101	110	118	130	57	59
Common Stock Par Or Stated Value Per Share	0.001	0.001	0	0.001	0.001	0.001	0	0.001	0.001	0.001	0	0.001
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	126	124	122	122	99	99	91	91	91	90	69	67
Shares Outstanding	126	124	122	122	99	99	91	91	91	90	69	67

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-4.84%	1.21%	-9.93%	-	-	-	-	-	-	-	-	-
2025	24.91%	30.53%	34.04%	40.41%	50.26%	76.68%	3.17%	-0.17%	-46.00%	-8.01%	-6.64%	-5.72%
2024	-14.79%	-23.08%	13.02%	33.24%	38.82%	61.47%	-1.17%	-31.65%	-40.00%	8.24%	2.87%	-15.77%
2023	-	-	-	-	-	-	46.63%	23.93%	46.63%	1.67%	-2.86%	-26.97%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	7.19	4.10	3.14	5.93	3.53	4.87	4.68	6.37	7.49	6.28	2.24	1.76
Quick Ratio	6.54	3.70	2.92	5.51	3.13	4.32	4.18	5.78	6.90	5.73	1.77	1.39
Working Capital	102.02M	98.43M	101.66M	126.10M	58.57M	70.87M	69.36M	81.42M	90.12M	95.32M	22.66M	18.40M
Leverage & Debt
Debt to Equity	-3.33	-5.14	-5.77	-40.81	-2.29	-2.68	-2.69	-3.42	-4.31	-4.57	-1.54	-1.58
Interest Coverage TTM	-4.68	-4.97	-6.39	-5.02	-4.73	-3.70	-2.77	-1.99	-1.67	-2.53	-2.38	-3.83
Debt Ratio	1.43	1.24	1.21	1.03	1.77	1.60	1.59	1.41	1.30	1.28	2.85	2.73
Efficiency & Turnover
Asset Turnover TTM	0.48	0.41	0.34	0.32	0.42	0.47	0.72	0.70	0.67	0.54	0.88	0.86
Days Sales Outstanding TTM	62.94	49.86	102.86	-	-	-	50.14	-	-	-	61.13	-
Receivables Turnover TTM	5.80	7.32	3.55	-	-	-	7.28	-	-	-	5.97	-
Per Share Metrics
Diluted EPS TTM	-0.63	-0.56	-0.78	-0.62	-0.65	-0.57	-0.51	-0.39	-0.28	-0.39	-0.13	-0.19
Free Cash Flow Per Share TTM	-0.44	-0.36	-0.50	-0.25	-0.27	-0.51	-0.41	-0.38	-0.27	-0.36	-0.12	0.09
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	67.04%	63.45%	58.35%	60.28%	61.09%	68.40%	68.95%	69.39%	68.49%	60.23%	58.82%	55.35%
Operating Profit Margin TTM	-97.52%	-111.18%	-159.50%	-128.56%	-119.19%	-75.94%	-53.46%	-35.83%	-26.03%	-37.77%	-29.86%	-45.58%
Net Profit Margin TTM	-144.63%	-137.08%	-188.09%	-158.95%	-147.38%	-100.02%	-76.68%	-59.75%	-44.07%	-55.85%	-15.56%	-25.20%
Growth Metrics
Net Revenue Growth (1Y)	22.56%	-7.30%	-22.61%	-26.32%	-24.38%	5.29%	13.80%	22.56%	25.45%	10.65%	6.09%	-0.04%
Net Income Growth (1Y)	20.27%	27.05%	89.83%	96.00%	152.89%	88.55%	460.83%	190.59%	13.74%	-13.15%	-85.54%	-82.94%
EPS Growth (1Y)	-4.43%	-1.04%	53.97%	61.44%	131.47%	45.35%	296.12%	106.35%	-28.25%	-34.37%	-88.49%	-85.91%
Valuation Metrics
P/E TTM	-6.65	-7.38	-8.24	-8.96	-5.05	-5.11	-7.00	-12.89	-9.19	-10.90	-15.72	-8.17
P/B TTM	-9.19	-14.94	-20.52	-150.44	-4.53	-4.55	-5.13	-9.99	-6.66	-8.64	-1.16	-0.96
P/S TTM	9.61	10.12	15.51	14.24	7.45	5.11	5.36	7.70	4.05	6.09	2.45	2.06
Market Cap	519.98M	508.83M	690.75M	618.17M	328.77M	276.94M	308.75M	453.59M	236.37M	313.60M	123.74M	98.96M
Enterprise Value	472.14M	436.86M	607.09M	495.43M	271.41M	208.31M	269.73M	394.56M	164.00M	234.54M	127.39M	78.65M
Calculated Values
Free Cash Flow TTM	-54.63M	-44.37M	-53.05M	-27.47M	-26.54M	-49.04M	-35.92M	-34.37M	-24.91M	-26.60M	-7.38M	5.97M
Net Debt	-47.84M	-71.97M	-83.66M	-122.74M	-57.36M	-68.63M	-39.02M	-59.03M	-72.37M	-79.06M	3.66M	-20.31M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-23Sale

Owner: Krop, Julie

Title: -

Shares: 25,000

Price/Share: $5.02

Value: $125,500.00

Shares Owned: -

Relationship: Director

Ownership: Direct

2026-06-15Sale

Owner: Barber, Daniel

Title: President and CEO

Shares: 25,000

Price/Share: $4.16

Value: $104,000.00

Shares Owned: 635,574

Relationship: Officer

Ownership: Direct

2026-05-15Sale

Owner: Barber, Daniel

Title: President and CEO

Shares: 8,257

Price/Share: $4.29

Value: $35,422.53

Shares Owned: 660,574

Relationship: Officer

Ownership: Direct

2026-03-10Sale

Owner: Korczynski, Sherry

Title: Chief Commercial Officer

Shares: 15,741

Price/Share: $4.17

Value: $65,639.97

Shares Owned: 241,117

Relationship: Officer

Ownership: Direct

2026-03-10Sale

Owner: Toth, A Ernest Jr

Title: Chief Financial Officer

Shares: 58,254

Price/Share: $4.17

Value: $242,919.18

Shares Owned: 376,112

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-23	Krop, Julie	Director	-	Direct	Sale	25,000	5.02	$125,500.00	0	4
2026-06-15	Barber, Daniel	Officer	President and CEO	Direct	Sale	25,000	4.16	$104,000.00	635,574	4
2026-05-15	Barber, Daniel	Officer	President and CEO	Direct	Sale	8,257	4.29	$35,422.53	660,574	4
2026-03-10	Korczynski, Sherry	Officer	Chief Commercial Officer	Direct	Sale	15,741	4.17	$65,639.97	241,117	4
2026-03-10	Toth, A Ernest Jr	Officer	Chief Financial Officer	Direct	Sale	58,254	4.17	$242,919.18	376,112	4
2026-03-10	Braender, Lori J	Officer	Chief Legal Officer	Direct	Sale	40,102	4.17	$167,225.34	442,879	4
2026-03-10	Cioffi, Melina	Officer	SVP, Regulatory Affairs	Direct	Sale	25,311	4.17	$105,546.87	274,867	4
2026-03-10	Barber, Daniel	Officer	President and CEO	Direct	Sale	180,677	4.17	$753,423.09	1,004,753	4
2026-03-10	Boyd, Peter E.	Officer	Chief People Officer	Direct	Sale	29,814	4.17	$124,324.38	338,509	4
2026-03-10	Jung, Cassie	Officer	Chief Operating Officer	Direct	Sale	45,791	4.17	$190,948.47	274,980	4
2025-10-15	Kraus, Carl N	Officer	Chief Medical Officer	Direct	Sale	20,272	7.00	$141,904.00	282,475	4
2025-10-15	Jung, Cassie	Officer	Chief Operating Officer	Direct	Sale	67,575	7.01	$473,700.75	240,771	4
2025-10-15	Boyd, Peter E.	Officer	See Remarks	Direct	Sale	10,000	7.00	$70,000.00	268,323	4
2025-09-26	Barber, Daniel	Director,Officer	President and CEO	Direct	Sale	91,343	6.03	$550,798.29	923,430	4
2025-09-26	Boyd, Peter E.	Officer	See Remarks	Direct	Sale	10,000	6.30	$63,000.00	278,323	4
2025-09-19	Barber, Daniel	Director,Officer	President and CEO	Direct	Sale	400	6.00	$2,400.00	1,014,773	4
2025-09-05	Boyd, Peter E.	Officer	See Remarks	Direct	Sale	15,000	5.30	$79,500.00	288,323	4
2025-09-04	Jung, Cassie	Officer	Chief Operating Officer	Direct	Sale	62,180	5.00	$310,900.00	283,346	4
2024-11-26	Jung, Cassie	Officer	Chief Operating Officer	Indirect	Sale	44	4.87	$214.28	0	4
2024-03-15	Schobel, Alexander Mark	Officer	Chief Innovation/Tech Officer	Direct	Sale	50,000	6.00	$300,000.00	984,476	4
2024-03-08	Schobel, Alexander Mark	Officer	Chief Innovation/Tech Officer	Direct	Sale	25,000	5.19	$129,750.00	1,040,371	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

52.89%

Inst. Shares: 64,843,906

Shares Outstanding: 122,609,995

2025-12-31

65.46%

Inst. Shares: 69,992,328

Shares Outstanding: 106,926,528

2025-09-30

56.86%

Inst. Shares: 62,875,646

Shares Outstanding: 110,584,371

2025-06-30

46.33%

Inst. Shares: 46,013,722

Shares Outstanding: 99,326,701

2025-03-31

44.80%

Inst. Shares: 42,786,149

Shares Outstanding: 95,497,056

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	64,843,906	122,609,995	52.89%
2025-12-31	69,992,328	106,926,528	65.46%
2025-09-30	62,875,646	110,584,371	56.86%
2025-06-30	46,013,722	99,326,701	46.33%
2025-03-31	42,786,149	95,497,056	44.80%
2024-12-31	42,067,083	86,726,211	48.51%
2024-09-30	45,351,652	91,082,081	49.79%
2024-06-30	41,355,314	90,911,626	45.49%
2024-03-31	38,760,550	73,614,710	52.65%
2023-12-31	21,896,941	61,255,864	35.75%
2023-09-30	21,107,297	64,678,761	32.63%
2023-06-30	17,668,795	57,350,902	30.81%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Aquestive Therapeutics, Inc. (AQST) — SEC Financial Statements & Analysis

Aquestive Therapeutics, Inc. (AQST) is a pharmaceutical preparations company, incorporated in DE. Aquestive Therapeutics, Inc. trades on Nasdaq as: AQST. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Aquestive Therapeutics, Inc. reported a 22.56% year-over-year revenue growth, a Gross Profit Margin of 67.04% (TTM), a Debt-to-Equity ratio of -3.33x, a Price-to-Sales (P/S) ratio of 9.61x (TTM), a Price-to-Book (P/B) ratio of -9.19x (TTM), at a market cap of $519.98M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 22.56%
Gross Profit Margin TTM: 67.04%
Debt To Equity: -3.33x
P/S TTM: 9.61x
P/B TTM: -9.19x
Market Cap: $519.98M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Aquestive Therapeutics, Inc. in?

Aquestive Therapeutics, Inc. (AQST) operates in the Pharmaceutical Preparations industry.

What is AQST's market cap?

Aquestive Therapeutics, Inc. (AQST) has a market capitalization of $519.98M as of 2026-06-30.

What exchange does AQST trade on?

Aquestive Therapeutics, Inc. (AQST) trades on the Nasdaq.

Where is Aquestive Therapeutics, Inc. incorporated?

Aquestive Therapeutics, Inc. is incorporated in DE.